Therapeutic Potential of GLP-1 Receptor Agonists in Metabolic Associated Steatotic Liver Disease DOI
Klaudia Nowak, Krzysztof Łupina,

Anna Romac

et al.

Annals of Pharmacotherapy, Journal Year: 2025, Volume and Issue: unknown

Published: March 12, 2025

Objective: To summarize the current knowledge on therapeutic potential of GLP-1 receptor agonists in managing metabolic associated steatotic liver disease (MASLD). Data Sources: A literature review was conducted using search terms , MASLD NAFLD nonalcoholic fatty treatment and therapy PubMed (from January 1, 2019, through February 2025), National Institutes Health (NIH) Scopus World Organization (WHO) data. Study Selection Extraction: All relevant clinical trials, articles, package inserts, guidelines evaluating clinically evidence regarding were considered for inclusion. Synthesis: RAs have shown promising results treatment. Semaglutide has demonstrated efficacy reducing fat content, inflammation, fibrosis, with trials indicating improvements hepatic biomarkers cardiometabolic risk factors. Similarly, tirzepatide been substantial weight loss significant reductions fibrosis markers. Both agents exert their effects mechanisms involving improved insulin sensitivity, reduced lipid accumulation, attenuation inflammation. Relevance to Patient Care Clinical Practice: Given high prevalence patients obesity type 2 diabetes, semaglutide could play a critical role practice by addressing multiple facets disease. fat, improving biomarkers, mitigating risks, which are leading causes morbidity mortality patients. Incorporating these therapies into significantly enhance patient outcomes targeting both liver-related systemic complications Conclusions: GLP1 show great promoting loss, glycemic control,

Language: Английский

Therapeutic Potential of GLP-1 Receptor Agonists in Metabolic Associated Steatotic Liver Disease DOI
Klaudia Nowak, Krzysztof Łupina,

Anna Romac

et al.

Annals of Pharmacotherapy, Journal Year: 2025, Volume and Issue: unknown

Published: March 12, 2025

Objective: To summarize the current knowledge on therapeutic potential of GLP-1 receptor agonists in managing metabolic associated steatotic liver disease (MASLD). Data Sources: A literature review was conducted using search terms , MASLD NAFLD nonalcoholic fatty treatment and therapy PubMed (from January 1, 2019, through February 2025), National Institutes Health (NIH) Scopus World Organization (WHO) data. Study Selection Extraction: All relevant clinical trials, articles, package inserts, guidelines evaluating clinically evidence regarding were considered for inclusion. Synthesis: RAs have shown promising results treatment. Semaglutide has demonstrated efficacy reducing fat content, inflammation, fibrosis, with trials indicating improvements hepatic biomarkers cardiometabolic risk factors. Similarly, tirzepatide been substantial weight loss significant reductions fibrosis markers. Both agents exert their effects mechanisms involving improved insulin sensitivity, reduced lipid accumulation, attenuation inflammation. Relevance to Patient Care Clinical Practice: Given high prevalence patients obesity type 2 diabetes, semaglutide could play a critical role practice by addressing multiple facets disease. fat, improving biomarkers, mitigating risks, which are leading causes morbidity mortality patients. Incorporating these therapies into significantly enhance patient outcomes targeting both liver-related systemic complications Conclusions: GLP1 show great promoting loss, glycemic control,

Language: Английский

Citations

0